Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response of the Urothelial Carcinoma Cell Lines to Cisplatin

18 Oct 2022

Abstract excerpt

Cisplatin (CDDP)-based chemotherapy is the standard of care in patients with muscle-invasive bladder cancer. However, in a large number of cases, the disease becomes resistant or does not respond to CDDP, and thus progresses and disseminates. In such cases, prognosis of patients is very poor. CDDP manifests its cytotoxic effects mainly through DNA damage induction. Hence, response to CDDP is mainly dependent on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to DNA Repair Mechanisms
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36293346
DOI: 10.3390/ijms232012488

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response of the Urothelial Carcinoma Cell Lines to CisplatinPMID 36293346Read ↗

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell LinesSemantic proximity Read ↗

Recommendations for the optimal management of early and advanced urothelial carcinoma.Semantic proximity Read ↗

CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancerSemantic proximity Read ↗

Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.Semantic proximity Read ↗

Bladder cancer: Mutations in DNA-damage-repair pathways confer platinum sensitivity.Semantic proximity Read ↗

Attenuated expression of xeroderma pigmentosum group C is associated with critical events in human bladder cancer carcinogenesis and progression.Semantic proximity Read ↗

Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell linesSemantic proximity Read ↗

Genetic determinants for chemo- and radiotherapy resistance in bladder cancerSemantic proximity Read ↗

Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?Semantic proximity Read ↗

Can Cisplatin Therapy Be Improved? Pathways That Can Be TargetedSemantic proximity Read ↗

New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatmentSemantic proximity Read ↗

p53 and chemosensitivity in bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.